Developing a new cell therapy to combat drug resistance in lung cancer
Personalization and Failure Testing of Dual Switch Gene Drives in Lung Cancer
['FUNDING_U01'] · PENNSYLVANIA STATE UNIVERSITY, THE · NIH-10977532
This study is testing a new type of cell therapy for people with non-small-cell lung cancer that helps the treatment adapt to the cancer's changes, making it more effective against drug resistance.
Quick facts
| Phase | ['FUNDING_U01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | PENNSYLVANIA STATE UNIVERSITY, THE (nih funded) |
| Locations | 1 site (UNIVERSITY PARK, UNITED STATES) |
| Trial ID | NIH-10977532 on ClinicalTrials.gov |
What this research studies
This research focuses on creating a novel cell therapy designed to address the challenge of drug resistance in patients with non-small-cell lung cancer (NSCLC). By utilizing synthetic biology, the therapy aims to engineer tumor evolution in real-time, allowing the cells to adapt and respond to changing therapeutic environments. The approach involves dual-switch gene drives that can sense and react to specific molecules, providing a dynamic response to drug resistance mechanisms. Patients may benefit from a more effective treatment option that can outsmart the cancer's ability to resist therapies.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with non-small-cell lung cancer who have experienced drug resistance to current therapies.
Not a fit: Patients with lung cancer types other than non-small-cell lung cancer may not receive benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for lung cancer patients by overcoming drug resistance.
How similar studies have performed: While the approach of using synthetic biology in cancer treatment is innovative, similar strategies have shown promise in other areas of cancer research.
Where this research is happening
UNIVERSITY PARK, UNITED STATES
- PENNSYLVANIA STATE UNIVERSITY, THE — UNIVERSITY PARK, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: PRITCHARD, JUSTIN — PENNSYLVANIA STATE UNIVERSITY, THE
- Study coordinator: PRITCHARD, JUSTIN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancer Biology, Cancer Genes, Cancer Patient, Cancer cell line, Cancer-Promoting Gene